©2022 Stanford Medicine
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
Not Recruiting
Trial ID: NCT04167761
Purpose
The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i)
medications enhance beneficial properties of epicardial adipose tissue including metabolic
flexibility, insulin sensitivity, decreased cell size and reduced inflammation.
Official Title
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
Stanford Investigator(s)
Tracey McLaughlin
Professor of Medicine (Endocrinology)
Eligibility
Inclusion Criteria:
- patient at Stanford Cardiovascular Surgery clinic who is scheduled for cardiac bypass
surgery
- history of Diabetes Mellitus Type 2 currently taking metformin or diet-controlled
Exclusion Criteria:
- allergy or intolerance to interventional medication
- currently taking any anti-diabetic medication other than metformin
Intervention(s):
drug: Ertugliflozin
drug: Glipizide
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Tracey McLaughlin, MD
650-736-2056